CommentAfter CAPRISA 004: time to re-evaluate the HIV lexicon
References (7)
- et al.
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward
Lancet
(2008) - et al.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
Science
(2010) - et al.
Whither or wither microbicides?
Science
(2008)
Cited by (29)
Contextual Factors Associated with Sexually Transmitted Infections
2013, Sexually Transmitted DiseasesGenital and Perinatal Herpes Simplex Virus Infections
2013, Sexually Transmitted DiseasesContextual Factors Associated with Sexually Transmitted Infections
2012, Sexually Transmitted Diseases: Vaccines, Prevention, and ControlGenital and Perinatal Herpes Simplex Virus Infections
2012, Sexually Transmitted Diseases: Vaccines, Prevention, and ControlMicrobicides: Still a long road to success
2012, Trends in MicrobiologyCitation Excerpt :In general, to date, more than 70 preclinical microbicide trials and 50 clinical trials of different phases have been performed (see www.microbicide.org). One of the important and unexpected results of CAPRISA 004 was a significant 51% reduction of the rate of acquisition of HSV-2, a common HIV-1 copathogen which facilitates HIV-1 transmission [54]. This effect was not anticipated, because in in vitro studies tenofovir showed no anti-HSV activity at the concentrations corresponding to systemic administration [55], whereas higher concentrations were considered to be nonphysiological.
Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication
2011, Cell Host and MicrobeCitation Excerpt :Tenofovir convincingly diminished HIV-1 transmission (by 39%). Surprisingly, in the CAPRISA 004 trial, a significant 51% reduction of the risk of acquiring HSV-2, a common HIV-1 copathogen that facilitates HIV transmission, was also observed (Cates, 2010). This effect of tenofovir gel on HSV was rather unanticipated because this highly potent antiretroviral and antihepadnaviral drug has been previously shown to exhibit minimal, if any, anti-HSV activity (Balzarini et al., 1993).